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Background/aim: Environmental and genetic factors may play a major role in the development of nonalcoholic fatty liver disease
(NAFLD) among people with obesity and type 2 diabetes mellitus. Based on the fact that PGC-1α, as the protein encoded by the
PPARGC1A gene, plays a key role in energy metabolism pathways, it has been hypothesized that polymorphisms within the PPARGC1A
gene may be associated with increased risks of NAFLD. Thus, this study was designed to evaluate the Gly482Ser polymorphism
(rs8192678) within the PPARGC1A gene and its association with the increased risk of NAFLD in Iranian patients with type 2 diabetes.
Materials and methods: A total of 145 NAFLD patients with a history of type 2 diabetes and 145 healthy control subjects were included
in the study. Gly482Ser polymorphism genotyping was done using the amplification refractory mutation system-polymerase chain
reaction (ARMS-PCR) technique.
Results: The results showed a significant difference between the PPARGC1A Gly482Ser polymorphism in NAFLD patients and the
healthy controls. Accordingly, the AA genotype and A allele were increased in the NAFLD patients when compared to the healthy
controls. However, no significant correlation was observed between the Gly482Ser polymorphism and the physiological and biochemical
parameters.
Conclusion: Based on the results, the AA genotype, which is associated with the insertion of Ser, can be considered as a risk factor for
the development of NAFLD in Iranian patients with diabetes type 2.
Key words: Nonalcoholic fatty liver disease, PPARGC1A gene, Gly482Ser polymorphism, type 2 diabetes

1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is one of the
most common forms of chronic liver disorder in developed
countries, and it affects more than 70% of patients with type
2 diabetes mellitus and people suffering from obesity [1,2].
NAFLD is characterized by hepatic and systemic insulin
resistance, dyslipidemia, and persistent abnormalities in the
liver enzymes [3–5]. NAFLD comprises a broad spectrum
of disease severity, ranging from benign hepatocellular
steatosis to nonalcoholic steatohepatitis (NASH-fatty
changes with inflammation and hepatocellular damages),
advanced liver cirrhosis, hepatocellular carcinoma, and
increased risk of liver-related mortalities [6].

Inherited factors, along with environmental factors,
play an important role in the development of NAFLD [2].
PPARGC1A is one of the strongest biological candidate
genes for susceptibility to NAFLD. The peroxisome
proliferator-activated receptor-gamma coactivator-1 alpha
(PGC-1α) protein is encoded by this gene and plays a
role in energy metabolism, including insulin resistance,
oxidative phosphorylation, hepatic gluconeogenesis,
and mitochondrial biogenesis and respiration, which are
important in the development of NAFLD [6]. Moreover,
there are some reports regarding the role of PGC-1α in
the homeostatic control of systemic energy metabolism,
regulation of lipid and carbohydrate metabolism,
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development of obesity, and control of blood pressure
[7,8].
Recent investigations have indicated that single
nucleotide polymorphisms (SNPs) of the PPARGC1A gene
may be associated with the susceptibility and progression of
NAFLD, obesity, type 2 diabetes mellitus, and hypertension
in various ethnicities [9,10]. Previous studies reported an
association between PPARGC1A polymorphism at position
+1564G/A (rs8192678) with NAFLD, which is associated
with the replacement of Gly with Ser (Gly482Ser) [10–12].
However, this polymorphism in the Iranian population
has not yet been studied and needs to be explored.
Thus, this study was designed to investigate the
association between Gly482Ser polymorphism within the
PPARGC1A gene and increased susceptibility to NAFLD
in Iranian subjects.
2. Materials and methods
A total of 145 Iranian NAFLD patients and 145 healthy
control subjects were recruited to participate in this
study. NAFLD was confirmed by liver biopsy in all 145
patients. Exclusion criteria for the NAFLD patients were
the presence of either ballooning cells or perisinusoidal/
pericellular fibrosis in zone 3 of the hepatic acinus, and
lobular inflammation, in addition to steatosis [10].

Moreover, the selection criteria included no history of
infections, autoimmunity, alcohol- or drug-induced
hepatitis, sclerosing cholangitis, α1-antitrypsin deficiency,
primary biliary cirrhosis, hemochromatosis, Wilson’s
diseases, or alcohol consumption.
The age- and sex-matched control subjects, who had
normal abdominal ultrasonography, were confirmed to
have normal liver functions and no metabolic diseases,
viral hepatitis, or alcohol abuse. All of the control subjects
had normal systolic (<132 mmHg) and diastolic blood
pressures (<85 mmHg), total cholesterol levels (<200 mg/
dL), fasting glucose (<90–100 mg/dL), and body mass
indices (BMIs) (<25 kg/m2). The characteristics of the
NAFLD patients and control subjects are presented in
Table 1.
Written informed consent was obtained from all
participants. The study was approved by the institutional
ethics committee and conducted in accordance with
the Declaration of Helsinki. The body weights of the
participants were measured using a calibrated electronic
scale, and venous blood samples were obtained after an
overnight fast (12 h). The total serum cholesterol, highdensity lipoproteins (HDL), hemoglobin A1c (HbA1c),
and triglyceride levels were measured via the enzymatic
method (commercial Analco kit, Poland). The low-density

Table 1. Characteristics of the NAFLD patients and healthy control subjects.
Characteristics

Control

NAFLD

P-value

Men/women

71/74

72/73

0.831

Age (years)

51.3 ± 10

53.9 ± 9

0.423

Weight (kg)

86.3 ± 4.4

89.2 ± 3.8

0.577

Systolic blood pressure (cmHg)

13.12 ± 1.98

13.95 ± 2.48

0.001

Diastolic blood pressure (cmHg)

8.36 ± 0.94

8.02 ±1.18

0.002

BMI (kg/m )

24.6 ± 2.6

29.4 ± 4.5

0.179

FBS (mg/dL)

89.6 ± 13.1

182.1 ± 20.3

0.572

Total cholesterol (mg/dL)

198.8 ± 34.1

204.1 ± 28.4

0.1

2h plasma glucose (mg/dL)

120.41 ± 12.40

240.19 ± 20.15

0.012

HDL-C (mg/dL)

45.0 ± 7.3

49.0 ± 9.7

0.490

LDL-C (mg/dL)

98.03 ± 12.5

103.0 ± 21.2

0.471

TG (mg/dL)

99 ± 40.4

112 ± 36.09

0.112

Cr (mg/dL)

0.96 ± 0.2

1.02 ± 0.42

0.031

HbA1c (%)

6.23 ± 3.0

8.63 ± 1.2

0.267

Microalbumin (mg/dL)

11.12 ± 5.6

19.03 ± 6.6

0.420

2

Data are mean ± SD; NAFLD: nonalcoholic fatty liver disease, BMI: body mass index, FBS: fasting blood
sugar, HDL-C: high-density lipoprotein-cholesterol, LDL-C: low-density lipoprotein-cholesterol, TG:
triglycerides, Cr: creatine.

1090

SAREMI et al. / Turk J Med Sci
lipoprotein (LDL) cholesterol levels were calculated using
the formula of Friedewald [13].
Genomic DNA was isolated from whole blood samples
using the Bioneer DNA extraction kit (AccuPrep Genomic
DNA Extraction Bioneer Kit, Republic of Korea).
Gly482Ser polymorphism genotyping was performed
using the amplification refractory mutation system
(ARMS)-polymerase chain reaction (PCR) method. The
ARMS technique uses allele-specific sequencing primers
and the amplification arrest caused by noncomplementary
nucleotide(s), located at the 3’ end of the primer. In this
study, a mutation-specific primer was used, resulting in the
formation of an additional product only in the presence
of the A allele. A total of 3 primers were used, as follows:
two forward primers, 5’ GACGAAGCAGACAAGACCG
3’
and
5’
GACGAAGCAGACAAGACCA
3’,
and
one
common
reverse
primer,
5’
AGAGTTAAAAGAAGAACAAGAAGGAG 3’.
Thermal cycling was carried out under the following
conditions: 95 °C for 5 min, and then 30 cycles at 95 °C
for 30 s, 56.5 °C for 30 s, and 72 °C for 30 s. This was
followed by incubation at 72 °C for 5 min. Agarose gel
electrophoresis was used to detect the stained 210-bp PCR
products (Figure).
SPSS software (IBM Corp., Armonk, NY, USA) was
used for data analysis. Categorical variables including the
frequencies of the genotypes and alleles were compared
using chi-square analysis and continuous variables by the
Student t-test. The odds ratio (OR) and its 95% confidence
interval (CI) were calculated to estimate the strength of
the association between patients and controls and the
polymorphism genotype alleles. Physical and laboratory
data are presented as means ± standard deviations (SDs).
P < 0.05 was regarded as statistically significant.
3. Results
The genotype and allele frequencies of the Gly482Ser
polymorphism are shown in Table 2. Genotypes AA and
AG were detected, but no homozygote for the PPARGC1A
mutation (GG) was found. The frequency of the AA and
AG genotypes in the NAFLD group was 120 and 25,
respectively, while in the control group, it was 105 and
40, respectively. Data analysis revealed that the genotypes
and alleles in both NAFLD patients and control subjects
were in Hardy–Weinberg equilibrium (Table 3). The chisquare test showed a significant difference between the
allele frequencies of the Gly482Ser polymorphism among
the patients and the controls (P < 0.05). As shown in Table
2, the frequency of A alleles in the NAFLD patients and
controls was 265 and 150, respectively, while for the G
allele it was 25 and 40. The statistical analysis revealed a
significant difference between the groups regarding the
PPARGC1A A and G alleles (P = 0.002).

Figure. Gly482Ser polymorphism in the PPARGC1A gene. M:
100-bp ladder molecular size marker. Lanes 1 and 4: 210-bp
PCR product. Lanes 1 and 2: AA genotype. Lanes 3 and 4: AG
genotype.

The significant differences in the genotype and allele
distributions between the two groups (P < 0.01) suggested
that there was a significant relationship between the
distribution of this polymorphism and NAFLD status.
The heterozygote AA genotype was associated with a
significantly higher risk of NAFLD (P < 0.01; adjusted
OR = 1.829, 95% CI = 1.04–3.215) compared with the
AG genotype. Statistical analysis also revealed that the A
allele in NAFLD patients was significantly associated with
increased risks of NAFLD (adjusted OR = 2.01, 95% CI =
1.41–3.47) in our population (P = 0.002).
Analysis of the association between the two genotypes
with the physiological and biochemical parameters in
the patients and controls is presented in Table 4, where it
can be seen that no significance difference was found in
these parameters (BMI, FBS, HbA1c, macroalbuminuria,
creatine, and lipid profile [TG, TC, HDL-C, and LDL-C]
levels) and the AA and AG genotypes between the patients
and controls. However, total cholesterol, LDL, and HDL
levels can be considered as independent risk factors for
NAFLD.
4. Discussion
NAFLD is a major public health problem and a hepatic
manifestation of the metabolic syndrome, with an even
higher risk in individuals with obesity and type 2 diabetes
[1,2]. Patients with NAFLD and type 2 diabetes present
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Table 2. Genotypic association of the Gly482Ser polymorphism with NAFLD.
Genotype
n = 145

Variable

AA

AG

NAFLD patients

120

25

Control subjects

105

40

Alleles

Variable

A

G

NAFLD patients

265

25

Control subjects

250

40

OR (95% CI)

P-value

1.829 (1.04–3.215)

0.035

OR (95% CI)

P-value

2.01 (1.41–3.47)

0.002

Table 3. Observed and expected frequencies among the NAFLD patients and control subjects using
Hardy–Weinberg equilibrium.
Groups

NAFLD
patients

Controls

Genotypes

Allele A

Allele G

Observed
frequency

Expected
frequency

AA

120

240

0

120

121.08

AG

25

25

25

25

22.84

GG

0

0

0

0

1.08

Total

145

265

25

145

145.00

AA

105

210

0

105

107.76

AG

40

40

40

40

34.48

GG

0

0

0

0

2.76

Total

145

250

40

145

145.00

P-value

0.2560

0.0540

As shown above, the frequencies of either the genotypes or alleles in both groups were in Hardy–
Weinberg equilibrium.
Table 4. Analysis of the physiologic variables in the control and case groups.

Variable

Control subjects

NAFLD patients

AA

AG

P-value

AA

AG

P-value

N

105

40

-

120

25

-

BMI (kg/m2)

24.6 ± 3.5

24.5 ± 3.4

0.86

29.4 ± 4.7

29.2 ± 4.4

0.75

FBS (mg/dL)

89.6 ± 9.1

87.4 ± 9

0.15

190.2 ± 20.2

182.1 ± 20.3

0.57

Total cholesterol (mg/dL)

48 ± 1.6

44.7 ± 1.7

0.2

42.2 ± 1.8

48.5 ± 1.8

0.92

HDL-C (mg/dL)

39.7 ± 10.3

39.7 ± 11.8

0.96

52.4 ± 11.9

49.7 ± 11.9

0.2

LDL-C (mg/dL)

50.6 ± 13.3

52.4 ± 12

0.4

88.1 ± 32.2

89.9 ± 35.3

0.76

TG (mg/dL)

76.5 ± 1.5

71.9 ± 1.5

0.99

110.1 ± 2

104.2 ± 2

0.77

Cr (mg/dL)

1 ± 0.3

1.1 ± 0.4

0.52

1 ± 0.3

1 ± 0.31

0.61

HbA1c (mg/dL)

6.8 ± 1.5

6.4 ± 1.6

0.76

8.3 ± 1.9

8.5 ± 2

0.90

Microalbumin (mg/dL)

6.3 ± 1.9

6.8 ± 2.1

0.18

20.7 ± 7

20.6 ± 6.8

0.91

Data are shown as mean ± SD; NAFLD: nonalcoholic fatty liver disease, BMI: body mass index, FBS: fasting blood sugar,
HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol, TG: triglycerides, Cr: creatine.
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higher levels of complications of diseases, including liver
cirrhosis, hepatocellular carcinoma, and death [14].
The protein encoded by the PPARGC1A gene (PGC1α) is a transcriptional factor that moderates the genes
involved in lipid and energy metabolism [10,11]. Previous
studies indicated that a deficiency of this protein results
in enhanced lipogenesis and hepatic steatosis. PGC-1α
interacts with PPAR-α, which is highly expressed in the
liver and coordinates the induction of fatty acid oxidation
in response to fasting. It also binds to PPAR-γ and activates
it to induce the expression of genes that are involved in
the differentiation of brown fat tissues. The binding of
PGC-1α to PPAR-γ permits the interaction of this protein
with multiple transcription factors [15]. PGC-1α also
plays a major regulatory role in mitochondria biogenesis
and glucose/fatty acid metabolism. Recent studies have
suggested the downregulation of PGC-1α-responsive
genes in insulin-resistant and type 2 diabetic subjects
[16]. Patti et al. analyzed the gene expression of PGC-1α
in diabetic Mexican-American subjects. They found that
insulin resistance and type 2 diabetes were associated with
decreased levels of PGC-1α in the skeletal muscle in both
diabetic and family history-positive nondiabetic subjects
[6]. Thus, genetic factors that alter the expression of the
molecule may participate in the pathogenesis of NAFLD.
In recent years, numerous related case-control
gene- and allele-associated studies have investigated the
association between single nucleotide polymorphisms
and the risk of disease in NAFLD patients. Particularly,
a common Gly482Ser polymorphism (rs8192678) of
the PPARGC1A gene was reported to be related to the
susceptibility of NAFLD in some ethnicities [10]. This
polymorphism may reduce PGC-1α activities and/or may
change its interaction with other transcription factors
required to regulate oxidative stress and lipid metabolism,
which finally triggers the pathogenesis of NAFLD in type 2
diabetic subjects. Gly482Ser polymorphism has also been
widely reported to be associated with an increased risk
of insulin resistance, obesity, and type 2 diabetes in some
populations [17–19].
Interestingly, the results of the current investigations
confirmed the plausible role of the Gly482Ser
polymorphism in the Iranian population. Accordingly,
the results revealed that both the AA genotype and A
alleles were significantly associated with a higher risk of
NAFLD. Additionally, based on the statistical analysis, the
AA genotype and A allele increased the risk of NAFLD by
1.82- and 2-fold when compared to the AG genotype and G
allele, respectively, in Iranian patients with type 2 diabetes.

In parallel with our results, several association studies have
demonstrated that the Gly482Ser polymorphism increases
the susceptibility to NAFLD in type 2 diabetic patients
[17–19]. This genotype distribution suggests a significant
association between PPARGC1A mutations and NAFLD
status. For example, Muller et al. reported that the AA
genotype could be associated with early insulin secretion
and altered lipid oxidation in a Pima Indian population
[18]. SNPs of the PPARGC1A gene were also shown to be
related to NAFLD in obese Taiwanese children [3]. Saremi
et al. observed that the rs8192678 SNP of the PPARGC1A
gene contributed to the onset of type 2 diabetes in Danish
patients [4]. However, a study by Hui et al. did not find any
association between the Gly482Ser variants and NAFLD
in Han Chinese people [20].
Collectively, based on our results, it seems that the
AA genotype and A allele can be considered important
risk factors for the induction of NAFLD in the Iranian
population.
A stratified analysis to assess the coimpacts of
Gly482Ser variations with other known risk factors for
NAFLD was accomplished here. For this purpose, the
associations of the two genotypes with the physiological
and biochemical variables, including BMI, FBS, creatine,
TG, plasma lipid levels, HbA1c, and microalbumin
levels, were investigated. The results revealed that none
of the biochemical parameters were associated with the
Gly482Ser polymorphism. Thus, it may be concluded that
although Gly482Ser variations were associated with an
increased risk of NAFLD in the Iranian population, their
role regarding the metabolism of lipids and glucose needs
to be explored by further investigation.
The limitation of this study was the low number of
diabetic patients with NAFLD available for the analysis.
Large-scale well-designed studies, matched case-controls,
and functional studies are great tools to support these
findings.
In conclusion, the results showed that the PPARGC1A
Gly482Ser polymorphism has an impact on NAFLD
susceptibility in the Iranian population. As a result, it
can be concluded that this gene polymorphism has an
important genetic contribution to the etiology of NAFLD
in patients with diabetes.
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